Cerevance is develops therapeutics for neurological and psychiatric disorders. Founded by Brad Margus and Mark Carlton in 2016, Cerevance is backed by investors that include Bill Gates, Dementia Discovery Fund, Foresite Capital, GV, Lightstone Ventures, and Takeda Ventures and is headquartered in Cambridge.